For the study, researchers analyzed the medical data of about 45 million Americans between 2011 and 2023. About 1 million people became new GLP-1 users during that period in time, results show.

A study by the Evernorth Research Institute looking at national prescription drug use trends found GLP-1 use between 2023-2024 rose 84.6% in Gen Alpha (ages 14 and younger). The age group was ...

A new study reports that of the 1 million new GLP-1 medication users identified between 2011 to 2023, there was a twofold increase in GLP-1 medication users who do not have type 2 diabetes.

The study found a sharp increase in the share of patients who received GLP-1 RAs during the study period, with GLP-1 RA use increasing 132.6% from the last six months of 2022 to the last six ...

GLP-1 drugs, such as Ozempic and the combination drug tirzepatide also included in the study, mimic a natural hormone known as glucagon-like peptide-1 to help regulate blood sugar and insulin levels.

Although the first GLP-1 drug was approved by the US Food and Drug Administration (FDA) in the early 2000s, it wasn't until a few years ago that its use became mainstream. Originally crafted to ...

The prevalence of U.S. adults without diabetes who filled a GLP-1 receptor agonist prescription rose from 0.1% in 2018 to 0.4% in 2022. As a result, annual spending jumped from $1.6 billion to $5. ...

“Challenges and opportunities” for food industry When researchers examined trends 12 months after GLP-1 use began, the impact on grocery and food-away-from-home spending was less pronounced.

Led by researchers at NYU Langone Health, the new study showed that those who were prescribed GLP-1 agonists, mostly within three years of receiving their transplant, were 49% less likely to ...

Overpaying for GLP-1 medications is extremely common, with a new data analysis of 102,166 drugs showing that 92% of those prescriptions could have been filled at a lower price. The DoseSpot analysis ...